<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476628</url>
  </required_header>
  <id_info>
    <org_study_id>H20-00842</org_study_id>
    <nct_id>NCT04476628</nct_id>
  </id_info>
  <brief_title>Efficacy of Budesonide Via Delayed Release vs Immediate Release</brief_title>
  <official_title>Prospective Double-Cohort Study: Comparing Efficacy of Budesonide Via Delayed Release vs Immediate Release After Administration in the Lying Head Back Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Paul's Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of intranasal budesonide administration with&#xD;
      lying head back position and a 5 mins time to release of medication (5MR) compared to 1 min&#xD;
      time to release (1MR) in chronic rhinosinusitis patients (CRS). Participants will be&#xD;
      instructed to administer via mucosal automatization device (MAD) with either of the two&#xD;
      treatment approaches daily for 5 to 7 days per week and 8 weeks total. This is a crossover&#xD;
      study design so each participants will be placed in the other treatment approach for an&#xD;
      additional 8 weeks of treatment. Moreover, there will be a &quot;washout&quot; of 2 weeks after&#xD;
      baseline assessment and before the first treatment, as well as a second &quot;washout&quot; of 2 weeks&#xD;
      between the two treatment approaches. The participants will also complete study related&#xD;
      procedures such as endoscopic evaluation, cultures, and two questionnaires throughout the&#xD;
      study period. The investigators hypothesize that Budesonide delivered to the sinuses with a 5&#xD;
      minute time to release of medication will be more effective at decreasing inflammation when&#xD;
      compared to a 1 minute time to release of medication after administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      To compare the efficacy of 1 minute versus 5 minutes time to release of budesonide with lying&#xD;
      head back position following administration via mucosal atomization device (MAD).&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Budesonide delivered to the sinuses with lying head back position and a 5 minute time to&#xD;
      release (5MR) of medication will be more effective at decreasing inflammation both&#xD;
      objectively and subjectively when compared to 1 minute time to release (1MR) of medication&#xD;
      after administration.&#xD;
&#xD;
      Baseline and Follow-up Visits Evaluation:&#xD;
&#xD;
      The following information will be obtained from each participant&#xD;
&#xD;
      Baseline Demographic Data: Age, sex, smoking status, CRS subtype, pre-existing comorbidities,&#xD;
      history of asthma, history of previous surgery, history of previous medications including&#xD;
      oral and inhaled corticosteroids.&#xD;
&#xD;
      Clinical Data: Modified Lund-Kennedy (MLK) scores, sinonasal cultures, Sino-nasal Outcome&#xD;
      Test-22 (SNOT-22), EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) scores, and culture.&#xD;
&#xD;
      Conduct of Study:&#xD;
&#xD;
      The proposed study is a single blind randomized, controlled crossover study at of 20 weeks in&#xD;
      duration. Participants who have CRS and who meet the inclusion and exclusion criteria, will&#xD;
      be invited to participate in this study.&#xD;
&#xD;
      Participants will undergo a 2 week &quot;washout&quot; period before starting their respective&#xD;
      administration method. The first administration methods will be once daily for 8 weeks in&#xD;
      duration. This is then followed by an additional &quot;washout&quot; period of 2 weeks. Finally,&#xD;
      participants will switch to the other administration method for an additional treatment&#xD;
      duration of daily application for 8 weeks. The goal is to assess which administration method&#xD;
      is more effective. Participants will be asked to administer budesonide daily with a minimum&#xD;
      requirement of at least five days a week to ensure changes seen are related to the&#xD;
      appropriate treatment arm. The &quot;washout&quot; period will involve standard of care daily&#xD;
      non-medicated intranasal saline irrigation. Data will be collected at baseline, 2 weeks, 10&#xD;
      weeks, 12 weeks, and lastly 20 weeks follow-up visit. SNOT-22 questionnaires, EQ-5D-5L&#xD;
      questionnaires, endoscopic evaluation, and Modified Lund Kennedy Scores will each be&#xD;
      completed at baseline and then again at 2 weeks, 10 weeks, 12 weeks, and 20 weeks.&#xD;
&#xD;
      Upon enrolment in the study, participants will be randomly divided to either start with 5MR&#xD;
      or 1MR administration methods through 1:1 block randomization. In addition, demographic data&#xD;
      and clinical data will be obtained by the investigators.&#xD;
&#xD;
      Management of Patient Care:&#xD;
&#xD;
      The clinical care remains the same for participants participating in this study; however,&#xD;
      there is a possibility that some participants will experience an increased frequency of&#xD;
      visits to the clinic with some being spaced 2 weeks apart. The increased appointments are&#xD;
      required to effectively transition each participants into the different treatment types and&#xD;
      also to acquire additional outcome measures. This will be clearly explained to each&#xD;
      participant to ensure that they are aware of the additional appointments compared to standard&#xD;
      of care. Otherwise, there are no additional risks imposed on the study participants.&#xD;
      Participants have the right to withdraw from the study at any time. Participants who meet any&#xD;
      of the exclusion criteria that were not noted at the beginning of the study will be removed&#xD;
      from this study and the physician will discuss the future management options with the&#xD;
      participant.&#xD;
&#xD;
      Sample Size:&#xD;
&#xD;
      A recruitment goal of 60 participants (30 participants per study arm) is expected to&#xD;
      demonstrate an effect for the study. To account for a drop-out rate of 25% the investigators&#xD;
      plan to recruit 40 participants in each arm.&#xD;
&#xD;
      The washout periods included in the crossover study design will allow for more control in&#xD;
      regards to reducing confounding variables. In particular, this allows participants to start&#xD;
      at a similar baseline by using the same standard of treatment with Budesonide for the 2 weeks&#xD;
      of washout before going into the 5MR or 1MR treatments.&#xD;
&#xD;
      Analysis:&#xD;
&#xD;
      Descriptive statistics will be used to analyze the baseline characteristic data and the data&#xD;
      from the administered surveys and objective findings of cultures and MLK scores. In addition,&#xD;
      rigorous statistical analysis will be conducted on the Likert scale-based SNOT-22 and&#xD;
      EQ-5D-5L surveys. These analyses will include paired t tests with repeated measured ANOVA for&#xD;
      validation and confidence intervals.&#xD;
&#xD;
      Safety Monitoring:&#xD;
&#xD;
      Participants who experience signs and symptoms of budesonide reaction will be noted and the&#xD;
      code will be broken so that a discussion can occur between the research supervisor and the&#xD;
      participants regarding the use.&#xD;
&#xD;
      All expected and unexpected adverse events will be recorded and graded by the research&#xD;
      supervisor. Stable chronic conditions, which are present prior to the clinical trial entry&#xD;
      and do not worsen, are not considered adverse events and will be accounted for in the&#xD;
      participant's medical history.&#xD;
&#xD;
      During each participant visit, the research supervisor will ask appropriate questions and&#xD;
      perform a physical exam to elicit any adverse events. The research supervisor will also&#xD;
      review any relevant clinical data and laboratory investigations with the partcicpant. All&#xD;
      reportable adverse events will be recorded on appropriate case report form. The research&#xD;
      supervisor will also write the stop date, the severity of the AE and his judgment of the AE's&#xD;
      relationship to the study.&#xD;
&#xD;
      A Serious Adverse Event (SAE) is defined as an AE meeting one of the following:&#xD;
&#xD;
      Death occurring between Day 0 and 182 days (6 months) of the study. Life Threatening Event&#xD;
      (defined as a participant at immediate risk of death at the time of the event) In-participant&#xD;
      hospitalization or prolongation of existing hospitalization between Day 0 and 42 of the&#xD;
      study.&#xD;
&#xD;
      Results in a persistent or significant disability/incapacity In the event of SAE, the&#xD;
      research supervisor will discuss with the partcipant (or next of kin) whether there is a&#xD;
      relationship between the study and the SAE. If there is a relationship, the PI will be&#xD;
      responsible for coordinating care for the participant until the SAE has been addressed.&#xD;
&#xD;
      Pregnancy During the Trial Participants will be responsible for determining if they are&#xD;
      pregnant or become pregnant during the study. If participants notify the PI they are&#xD;
      pregnant, they will be removed from the study and the medical management options will be&#xD;
      discussed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly divided to either start with 5MR or 1MR administration methods. They will undergo a 2 week &quot;washout&quot; period before starting their respective administration method. The first administration methods will be once daily for 8 weeks in duration. This is then followed by an additional &quot;washout&quot; period of 2 weeks. Finally, patients will switch to the other administration method for an additional treatment duration of daily application for 8 weeks. We will assess which administration method is more effective. Patients will be asked to administer budesonide daily with a minimum requirement of at least five days a week to ensure changes seen are related to the appropriate treatment arm. The &quot;washout&quot; period will involve standard of care daily non-medicated intranasal saline irrigation. Data will be collected at baseline, 2 weeks, 10 weeks, 12 weeks, and lastly 20 weeks follow-up visit.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Modified Lund Kennedy Score</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>This score is based on the endoscopic assessment of polyps, edema, and discharge and are each given score 0-2. It is out of a total score of 12 with higher scores indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sinonasal-Outcomes Test-22 (SNOT-22) Score</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>This is a standard of care baseline Sinonasal Outcome Test form that includes 22 questions about symptoms and social/emotional consequences of your nasal disorder. You will be asked to rate your problems as they have been over the past two weeks. An example of the questions is:&#xD;
Need to blow nose&#xD;
Sneezing It is out of a total of 110 and higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Score</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>This is a questionnaire that asks six multiple-choice questions about your mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health. It is out of a total score of 100 and higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sinus culture results</measure>
    <time_frame>baseline and 20 weeks</time_frame>
    <description>A swab will be taken from your nose to see if there are any bacteria or fungi present.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Budesonide 5MR then 1MR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.&#xD;
st time period: Patients will undergo a 2 week &quot;washout&quot; period. The &quot;washout&quot; period will involve standard of care daily non-medicated intranasal saline irrigation.&#xD;
nd time period: 5MR administration method once daily for 8 weeks in duration.&#xD;
rd time period: Patients will undergo a 2 week &quot;washout&quot; period of daily. The &quot;washout&quot; period will involve standard of care daily non-medicated intranasal saline irrigation.&#xD;
th time period: 1MR administration method once daily for 8 weeks in duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide 1MR then 5MR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.&#xD;
st time period: Patients will undergo a 2 week &quot;washout&quot; period. The &quot;washout&quot; period will involve standard of care daily non-medicated intranasal saline irrigation.&#xD;
nd time period: 1MR administration method once daily for 8 weeks in duration.&#xD;
rd time period: Patients will undergo a 2 week &quot;washout&quot; period of daily. The &quot;washout&quot; period will involve standard of care daily non-medicated intranasal saline irrigation.&#xD;
th time period: 5MR administration method once daily for 8 weeks in duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.</description>
    <arm_group_label>Budesonide 1MR then 5MR</arm_group_label>
    <arm_group_label>Budesonide 5MR then 1MR</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucosal Atomization Device</intervention_name>
    <description>MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.</description>
    <arm_group_label>Budesonide 1MR then 5MR</arm_group_label>
    <arm_group_label>Budesonide 5MR then 1MR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation</intervention_name>
    <description>INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.</description>
    <arm_group_label>Budesonide 1MR then 5MR</arm_group_label>
    <arm_group_label>Budesonide 5MR then 1MR</arm_group_label>
    <other_name>INSI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged between 19 years and above&#xD;
&#xD;
          2. Patients with chronic or recurrent sinusitis (as defined by the American Academy of&#xD;
             Otolaryngology) with or without nasal polyposis or allergic fungal rhinosinusitis.&#xD;
&#xD;
          3. Patients currently on budesonide or being prescribed budesonide for the first time&#xD;
&#xD;
          4. Minimum Modified Lund Kennedy score of 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals unable to understand the purpose, methods and conduct of this study&#xD;
&#xD;
          2. Patients unwilling to provide informed consent&#xD;
&#xD;
          3. Are immuno-compromised, and have impairment in mucociliary function (e.g., cystic&#xD;
             fibrosis, Kartagener syndrome)&#xD;
&#xD;
          4. Have autoimmune diseases affecting the upper airway (eg Systemic lupus erythematosus,&#xD;
             Sj√∂gren's syndrome, systemic sclerosis etc)&#xD;
&#xD;
          5. Have sinonasal tumors&#xD;
&#xD;
          6. Patients with a history of pituitary disease&#xD;
&#xD;
          7. Patients with a known hypersensitivity to cortisol, corticotropin, or cosyntropin&#xD;
&#xD;
          8. Recent use of systemic corticosteroids such as prednisone (within last 3 months)&#xD;
&#xD;
          9. Patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin JAver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of British Columbia and St. Paul's Sinus Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atenea Pascual</last_name>
    <phone>(604) 806-9926</phone>
    <email>apascual@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Samson</last_name>
    <phone>(604) 806-9926</phone>
    <email>lsamson2@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul's Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Amin Javer</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Budesonide</keyword>
  <keyword>MAD</keyword>
  <keyword>CRS</keyword>
  <keyword>Head Position</keyword>
  <keyword>Timing of Release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will publish final outcomes as scientific paper.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

